Sign in or create an account to add this stock to your watchlist.
About Rosetta Genomics (NASDAQ:ROSG)
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ROSG
CUSIPN/A
Phone972-73-222-0700
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$9.23 million
Price / Sales0.28
Cash FlowN/A
Price / CashN/A
Book Value$2.41 per share
Price / Book0.18
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees86
Outstanding Shares5,930,000
Rosetta Genomics (NASDAQ:ROSG) Frequently Asked Questions
What is Rosetta Genomics' stock symbol?
Rosetta Genomics trades on the NASDAQ under the ticker symbol "ROSG."
How were Rosetta Genomics' earnings last quarter?
Rosetta Genomics (NASDAQ:ROSG) announced its earnings results on Thursday, May, 19th. The medical research company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.02. The medical research company had revenue of $2.60 million for the quarter, compared to the consensus estimate of $3.36 million. View Rosetta Genomics' Earnings History.
Who are some of Rosetta Genomics' key competitors?
Some companies that are related to Rosetta Genomics include Uluru (ULUR), RXi Pharmaceuticals (RXII), Reliv (RELV), Sunwin Stevia International (SUWN), Marina Biotech (MRNA), Acura Pharmaceuticals (ACUR), International Stem Cell (ISCO), Auris Medical (EARS), Boston Therapeutics (BTHE), Immune Therapeutics (IMUN), EpiCept (IMNP), Bioblast Pharma (ORPN), Onconova Therapeutics (ONTX), Anthera Pharmaceuticals (ANTH) and ERBA Diagnostics (ERBA).
Who are Rosetta Genomics' key executives?
Rosetta Genomics' management team includes the folowing people:
- Mr. Kenneth A. Berlin, Pres & CEO (Age 54)
- Mr. Ron Kalfus CPA, Chief Financial Officer (Age 44)
- Mr. Oded Biran Adv., Gen. Counsel and Sec. (Age 39)
- Dr. Eti Meiri Ph.D., VP of Research (Age 50)
- Ms. Ana C. Ward Esq., M.S.,M.B.A., Exec. VP of Legal and Corp. Devel.
Has Rosetta Genomics been receiving favorable news coverage?
Media headlines about ROSG stock have been trending positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Rosetta Genomics earned a news sentiment score of 0.26 on Accern's scale. They also assigned news headlines about the medical research company an impact score of 46.96 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Rosetta Genomics' major shareholders?
Which major investors are buying Rosetta Genomics stock?
How do I buy shares of Rosetta Genomics?
Shares of ROSG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rosetta Genomics' stock price today?
One share of ROSG stock can currently be purchased for approximately $0.4299.
How big of a company is Rosetta Genomics?
Rosetta Genomics has a market capitalization of $2.55 million and generates $9.23 million in revenue each year. Rosetta Genomics employs 86 workers across the globe.
How can I contact Rosetta Genomics?
Rosetta Genomics' mailing address is 10 PLAUT STREET SCIENCE PARK, REHOVOT L3, 76706. The medical research company can be reached via phone at 972-73-222-0700 or via email at [email protected]
MarketBeat Community Rating for Rosetta Genomics (ROSG)
MarketBeat's community ratings are surveys of what our community members think about Rosetta Genomics and other stocks. Vote "Outperform" if you believe ROSG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ROSG will underperform the S&P 500 over the long term. You may vote once every thirty days.
Rosetta Genomics (NASDAQ:ROSG) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Rosetta Genomics in the last 12 months. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Buy |
| Consensus Rating Score: | 2.00 | 2.00 | 2.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | $3.50 |
| Price Target Upside: | N/A | N/A | N/A | 621.65% upside |
Rosetta Genomics (NASDAQ:ROSG) Consensus Price Target History
Rosetta Genomics (NASDAQ:ROSG) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Rosetta Genomics (NASDAQ:ROSG) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Rosetta Genomics (NASDAQ ROSG) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 22.80%
Rosetta Genomics (NASDAQ ROSG) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/26/2018 | Healthcare Master Fund Sabby | Major Shareholder | Buy | 7,085 | $0.35 | $2,479.75 | |  |
| 3/15/2018 | Healthcare Master Fund Sabby | Major Shareholder | Buy | 119,761 | $0.42 | $50,299.62 | | |
| 3/13/2018 | Healthcare Master Fund Sabby | Major Shareholder | Buy | 175,828 | $0.42 | $73,847.76 | | |
(Data available from 1/1/2013 forward)
Rosetta Genomics (NASDAQ ROSG) News Headlines
| Source: |
|
Rosetta Genomics (NASDAQ:ROSG) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Rosetta Genomics (NASDAQ:ROSG) Income Statement, Balance Sheet and Cash Flow Statement
Rosetta Genomics (NASDAQ ROSG) Stock Chart for Thursday, May, 24, 2018
Loading chart…
